Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Status:
Recruiting
Trial end date:
2025-09-04
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when
combined with the standard dose of azacitidine. Treatment will begin within 28 days of
screening procedures. Treatment will continue indefinitely, provided that the patient
continues to derive benefit. A patient will be taken off study for reasons described in
detail in section 3.12 including disease progression, unacceptable toxicity, inter-current
illness, withdrawal of consent, or at the discretion of the investigator. Patients will be
followed for 12 weeks after the last dose of study drug, until any study treatment related
toxicities have stabilized, or until death. The total duration of the study is expected to be
approximately 24 months.